ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2649
    “Point of Care” Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NPSLE)
  • Abstract Number: 2435
    ‘It’s like the Worst Toothache You’ve Ever Had’ – How Persons with Rheumatoid Arthritis Describe and Manage Pain in Daily Life
  • Abstract Number: L18
    14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
  • Abstract Number: 408
    14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
  • Abstract Number: 359
    14-3-3η Cit:Arg Antibody Ratios:  Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
  • Abstract Number: 362
    14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
  • Abstract Number: 405
    14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
  • Abstract Number: 658
    17β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis
  • Abstract Number: 465
    18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
  • Abstract Number: 2751
    18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
  • Abstract Number: 667
    24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings
  • Abstract Number: 1166
    5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
  • Abstract Number: 360
    88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
  • Abstract Number: 885
    A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
  • Abstract Number: 776
    A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA
  • 1
  • 2
  • 3
  • …
  • 202
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology